Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd.
  6. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD.

(4519)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Japan Exchange
12/01/2021 12/02/2021 12/03/2021 12/06/2021 12/07/2021 Date
3634 3665 3676 3528 3628 Last
2551900 2596100 2313000 2851700 3146500 Volume
-1.25% +0.85% +0.30% -4.03% +2.83% Change
Estimated financial data (e)
Sales 2021 974 B 8 581 M 8 581 M
Net income 2021 292 B 2 569 M 2 569 M
Net cash position 2021 461 B 4 059 M 4 059 M
P/E ratio 2021 20,5x
Yield 2021 1,90%
Sales 2022 1 006 B 8 861 M 8 861 M
Net income 2022 293 B 2 582 M 2 582 M
Net cash position 2022 593 B 5 226 M 5 226 M
P/E ratio 2022 20,4x
Yield 2022 2,08%
Capitalization 5 965 B 52 520 M 52 537 M
EV / Sales 2021 5,65x
EV / Sales 2022 5,34x
Nbr of Employees 7 555
Free-Float 37,8%
More Financials
Company
CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the... 
Sector
Pharmaceuticals
Calendar
02/03 | 03:00amEarnings Release
More about the company
Ratings of Chugai Pharmaceutical Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about CHUGAI PHARMACEUTICAL CO., LTD.
12/06CHUGAI PHARMACEUTICAL : CHMP Recommends EU Approval of Chugai's Actemra/RoActemra to Treat..
PU
12/06Chugai - Towa Pharmaceutical Receives Approval for Authorized Generic Version of Chugai..
AQ
12/03CHUGAI PHARMACEUTICAL : Towa Pharmaceutical Receives Approval for Authorized Generic Versi..
PU
12/02Chugai Launches a New Educational Website 'So-Zo LABO' Aiming for a Society that Embrac..
AQ
12/01CHUGAI PHARMACEUTICAL : Launches a New Educational Website “So-Zo LABO” Aiming..
PU
11/26Chugai Pharmaceutical Co. - Anti Cancer Agent Herceptin Approved for Additional Indicat..
AQ
11/25CHUGAI PHARMACEUTICAL : Anti-Cancer Agent Herceptin Approved for Additional Indication of ..
PU
11/23Beijing IP Court To Hear China's First Case Of Patent Linkage
AQ
11/18CHUGAI PHARMACEUTICAL : Personnel Changes
PU
11/18CHUGAI PHARMACEUTICAL : Script (including Q&A)
PU
11/16CHUGAI PHARMACEUTICAL : Atea Announces Update on Collaboration with Roche for AT-527
PU
11/16Chugai Continuously Selected in the 'DJSI World,' a Global ESG Investment Index
AQ
11/16CHUGAI PHARMACEUTICAL : Obtains Regulatory Approval for FoundationOne CDx Cancer Genomic P..
PU
11/16CHUGAI PHARMACEUTICAL : Hosted Discussion Series to Drive Quality Cancer Care in Developin..
PU
11/15CHUGAI PHARMACEUTICAL : Continuously Selected in the “DJSI World,” a Global ES..
PU
More news
News in other languages on CHUGAI PHARMACEUTICAL CO., LTD.
11/12Toshiba compte se scinder en trois entreprises d'ici deux ans
11/12Sous pression, Toshiba prévoit de se scinder en trois entreprises
11/12CHRONOLOGIE : Toshiba va de crise en crise depuis 2015.
11/11Toshiba va de crise en crise depuis 2015.
11/09PRESSE : Toshiba envisage une scission en trois entités
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD.
More recommendations
Chart CHUGAI PHARMACEUTICAL CO., LTD.
Duration : Period :
Chugai Pharmaceutical Co., Ltd. Technical Analysis Chart | 4519 | JP3519400000 | MarketScreener
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 3 628,00 JPY
Average target price 4 808,46 JPY
Spread / Average Target 32,5%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Chairman & Chief Executive Officer
Osamu Okuda President, COO & Representative Director
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD.-34.07%51 127
JOHNSON & JOHNSON3.53%428 955
ROCHE HOLDING AG17.23%322 390
PFIZER, INC.44.09%288 950
NOVO NORDISK A/S65.08%245 091
ELI LILLY AND COMPANY45.45%223 321